This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwenger, P.
Right arrow Articles by Vilcek, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwenger, P.
Right arrow Articles by Vilcek, J.

 Previous Article  |  Next Article 

Mol Cell Biol, January 1998, p. 78-84, Vol. 18, No. 1
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Activation of p38 Mitogen-Activated Protein Kinase by Sodium Salicylate Leads to Inhibition of Tumor Necrosis Factor-Induced Ikappa Balpha Phosphorylation and Degradation

Paul Schwenger,1 Deborah Alpert,1 Edward Y. Skolnik,2 and Jan Vilcek1,*

Department of Microbiology1 and Kaplan Cancer Center and Department of Pharmacology,2 Skirball Institute for Biomolecular Medicine, NYU Medical Center, New York, New York 10016

Received 7 August 1997/Returned for modification 17 September 1997/Accepted 6 October 1997

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Many actions of the proinflammatory cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1) on gene expression are mediated by the transcription factor NF-kappa B. Activation of NF-kappa B by TNF and IL-1 is initiated by the phosphorylation of the inhibitory subunit, Ikappa B, which targets Ikappa B for degradation and leads to the release of active NF-kappa B. The nonsteroidal anti-inflammatory drug sodium salicylate (NaSal) interferes with TNF-induced NF-kappa B activation by inhibiting phosphorylation and subsequent degradation of the Ikappa Balpha protein. Recent evidence indicated that NaSal activates the p38 mitogen-activated protein kinase (MAPK), raising the possibility that inhibition of NF-kappa B activation by NaSal is mediated by p38 MAPK. We now show that inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation by NaSal is prevented by treatment of cells with SB203580, a highly specific p38 MAPK inhibitor. Both p38 activation and inhibition of TNF-induced Ikappa Balpha degradation were seen after only 30 s to 1 min of NaSal treatment. Induction of p38 MAPK activation and inhibition of TNF-induced Ikappa Balpha degradation were demonstrated with pharmacologically achievable doses of NaSal. These findings provide evidence for a role of NaSal-induced p38 MAPK activation in the inhibition of TNF signaling and suggest a possible role for the p38 MAPK in the anti-inflammatory actions of salicylates. In addition, these results implicate the p38 MAPK as a possible negative regulator of TNF signaling that leads to NF-kappa B activation.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Mitogen-activated protein kinases (MAPKs) are proline-directed serine-threonine kinases that have important functions as mediators of cellular responses to a variety of extracellular stimuli (10, 34, 45). Three major subfamilies of structurally related MAPKs have been identified in mammalian cells: the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPKs), and the p38 kinases. Members of all three MAPK subfamilies are activated by upstream dual specificity kinases (MAPK kinases, or MKKs) which produce a simultaneous phosphorylation on threonine and tyrosine residues that are separated by one other amino acid. MAPK kinases, in turn, are activated by a family of serine-threonine kinases termed MAPK kinase kinases, or MEKKs. ERKs are characteristically activated by various growth factors and by phorbol esters. Members of the JNK/SAPK and p38 MAPK subfamilies are strongly activated in response to stress stimuli such as UV radiation, heat shock, and hyperosmolarity (27, 36, 43). JNK/SAPKs and p38s are also characteristically activated by the major proinflammatory cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1). The specificity of activating stimuli for the three subfamilies of MAPKs is not absolute; for instance, TNF and IL-1 are known to activate ERKs in many cell lines, and some growth factors can produce a weak activation of the JNK/SAPKs and p38 kinases (35, 46, 48, 53, 54). Whereas ERKs are characteristically associated with cell proliferation and protection from apoptosis, JNK/SAPKs and p38 kinases can promote apoptosis in many systems (17, 23, 24, 59). Ten isoforms of JNK/SAPKs (19) and four isoforms of p38 kinases (13, 21, 26, 28, 30) have been identified in mammalian cells. Among the identified substrates of MAPKs are a variety of transcription factors that become activated upon their phosphorylation (10, 34, 45, 56).

TNF and IL-1 are potent activators of gene expression, and many actions of these cytokines, including those that characteristically occur during inflammation, can be ascribed to their ability to activate the transcription factor NF-kappa B (2-4). In most vertebrate cells, NF-kappa B proteins are present in a latent form, sequestered in the cytoplasm by members of the Ikappa B family of inhibitory proteins. The two major forms of Ikappa B are Ikappa Balpha and Ikappa Bbeta (39). The release of active NF-kappa B proteins from the inactive complex and their translocation to the nucleus are initiated by site-specific phosphorylation of serine residues on Ikappa B proteins (serines 32 and 36 on Ikappa Balpha and serines 19 and 23 on Ikappa Bbeta ), which provides a signal for the ubiquitination and degradation of Ikappa B proteins by a proteasome-dependent pathway. The pathway leading to TNF-induced Ikappa Balpha phosphorylation has been recently elucidated. Cross-linking of the p55 TNF receptor (TNF-RI) by its ligand leads to the association of several intracellular adapter proteins with the death domain region of TNF-RI (20). One of the proteins present in the complex, termed TRAF2, then interacts with, and activates, a kinase termed NIK (NF-kappa B-inducing kinase), a member of the MAPK kinase kinase family (33). NIK in turn produces phosphorylation and activation of a kinase termed CHUK (12) or IKK-alpha , the enzyme capable of phosphorylating serines 32 and 36 on Ikappa Balpha (44). CHUK/IKK-alpha may also be responsible for phosphorylating Ikappa Bbeta , which provides an alternative route of TNF-induced NF-kappa B activation in some types of cells (44).

We have recently demonstrated the activation of p38 MAPK in cells after their treatment with sodium salicylate (NaSal), a nonsteroidal anti-inflammatory drug (NSAID) (47). To learn about the possible functional significance of NaSal-induced p38 kinase activation, we recently examined the effect of the pyridinyl imidazole compound SB203580, a selective p38 MAPK inhibitor (14, 29), on NaSal-induced apoptosis in cultured normal human diploid fibroblasts (47). Treatment with SB203580 protected human fibroblasts from programmed cell death, indicating that p38 MAPK activation was essential for NaSal-induced apoptosis in this cell system. The latter finding raised the possibility that p38 MAPK played a role in some other actions produced by NaSal or other NSAIDs. One recently discovered, extensively documented action of NaSal and its acetylated form, aspirin, is the inhibition of NF-kappa B activation (7, 9, 15, 16, 18, 25, 40, 42). In TNF-treated cells, NaSal was shown to inhibit NF-kappa B activation by preventing Ikappa Balpha phosphorylation and subsequent Ikappa Balpha degradation, but the pathway responsible for this inhibitory action has not been elucidated (25, 42). In the present study, we demonstrate that p38 kinase activation is required for the inhibitory action of NaSal on TNF-induced Ikappa Balpha phosphorylation and degradation. Our findings shed light on the pathway whereby NaSal inhibits TNF signaling leading to NF-kappa B activation. In addition, these results suggest that TNF-induced p38 kinase activation may exert a negative regulatory influence on the process of NF-kappa B activation by this cytokine.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell culture. COS-1 African green monkey kidney cells were cultured at 37°C in the presence of 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Before use in experiments, COS-1 cells were serum starved for 18 h in DMEM with 0.5% FBS. HT-29 human colon adenocarcinoma cells were cultured in DMEM with 8% FBS and before use in experiments were serum starved for 24 h in DMEM with 0.25% FBS.

Materials. The rabbit polyclonal anti-Ikappa Balpha antibody was purchased from Santa Cruz Biotechnology. The rabbit polyclonal anti-phospho-Ikappa Balpha , anti-phospho-p38 MAPK, and anti-p38 MAPK antibodies were obtained from New England Biolabs. The anti-phospho-Ikappa Balpha antibody is specific for phosphorylated serine 32 of Ikappa Balpha , and the anti-phospho-p38 antibody is specific for phosphorylated tyrosine 182 of p38 MAPK. Antibody specific for Ikappa Bbeta was purchased from Santa Cruz Biotechnology. Recombinant human TNF-alpha was supplied by Masafumi Tsujimoto, Suntory Institute for Biomedical Research, Osaka, Japan. Recombinant human IL-1alpha was obtained from the National Cancer Institute, Bethesda, Md. NaSal was purchased from Sigma and dissolved in distilled water. The p38 MAPK inhibitor SB203580 (29) was kindly supplied by John C. Lee and Peter Young (SmithKline Beecham, King of Prussia, Pa.) and was solubilized in dimethyl sulfoxide. Control experiments demonstrated that treatment with the same concentration of dimethyl sulfoxide alone had no effect on the ability of NaSal to inhibit TNF-induced Ikappa Balpha phosphorylation and degradation. At the concentration used (10 µM), SB203580 did not inhibit JNK/SAPK activity in an in vitro kinase assay using glutathione S-transferase-c-Jun as the substrate (data not shown).

Immunoblotting. Western blot analysis was performed essentially as described previously (47, 48). Briefly, whole-cell lysates were generated by using a buffer consisting of 1% Nonidet P-40, 50 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM EDTA, 1 mM pyrophosphate, 10 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 100 mM sodium fluoride. Equal amounts of lysates were subjected to sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis and then transferred to Immobilon-P membranes (Millipore) in transfer buffer (25 mM Tris, 192 mM glycine, 20% [vol/vol] methanol). Membranes were first rinsed in Tris-buffered saline (TBS; 10 mM Tris [pH 7.4], 150 mM NaCl) and then blocked overnight at room temperature in TBS-5% bovine serum albumin (BSA). The anti-Ikappa Balpha antibody was used at a dilution of 1:200 in TBS-5% BSA. The anti-phospho-Ikappa Balpha , anti-phospho-p38 MAPK, anti-p38 MAPK, and anti-Ikappa Bbeta antibodies were each used at a dilution of 1:1,000 in TBS-5% BSA. Antibody-antigen complexes were detected with the aid of horseradish peroxidase-conjugated protein A or horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (Bio-Rad) and a chemiluminescent substrate development kit (Kirkegaard & Perry Laboratories). For Ikappa Balpha blots, equal loading was ascertained by the presence of an ~70-kDa nonspecific band recognized by the anti-Ikappa Balpha antibody (not shown).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

NaSal strongly inhibits TNF-induced, but not IL-1-induced, Ikappa Balpha phosphorylation and degradation. To analyze the effect of NaSal on the TNF-induced degradation of Ikappa Balpha , COS-1 cells were treated for different time periods with TNF alone or with TNF in the presence of NaSal (Fig. 1A, upper panel). Treatment with TNF for 5 min resulted in the appearance of a slower-migrating Ikappa Balpha band, corresponding to the phosphorylated form of Ikappa Balpha (6, 38, 49). Disappearance of the Ikappa Balpha protein, as a consequence of its proteolytic degradation (6, 38, 49), was apparent at 10 and 15 min after TNF addition. In agreement with earlier reports (25, 42), treatment with NaSal completely inhibited TNF-induced degradation of Ikappa Balpha . Appearance of the phosphorylated form of Ikappa Balpha , visualized with the aid of an antibody specific for phospho-Ikappa Balpha , peaked at 5 min after TNF addition and was inhibited in the presence of NaSal (Fig. 1A, lower panel). Thus, in agreement with earlier findings (25, 42), our results indicate that NaSal inhibits Ikappa Balpha degradation by interfering with Ikappa Balpha phosphorylation, which is required for targeting Ikappa Balpha for degradation by the ubiquitin-proteasome pathway (41). Figure 1B shows that in the absence of NaSal, Ikappa Balpha protein begins to reappear in COS-1 cells by 30 min following TNF addition, and by 1 h after the onset of TNF treatment the levels approached those seen in untreated control cells. No change in the levels of Ikappa Balpha protein was seen in NaSal-treated cells at any of the examined time periods after TNF addition.


View larger version (51K):
[in this window]
[in a new window]
  		FIG. 1.   NaSal inhibits TNF-induced Ikappa Balpha phosphorylation and degradation. (A) COS-1 cells were either treated for 1 h with NaSal (20 mM) or left untreated. They were then either left unstimulated (Ctrl) or stimulated for the indicated times with TNF (20 ng/ml). Lysates were blotted with antibodies against Ikappa Balpha (top panel) or with antibodies to phosphorylated Ikappa Balpha (pIkappa B-alpha ; bottom panel). (B) COS-1 cells were treated as described above, and lysates were blotted with an anti-Ikappa Balpha antibody.

Our earlier studies indicated that NaSal produced a selective inhibition of TNF-induced signaling, as evidenced by the fact that NaSal suppressed the activation of ERK and JNK MAPKs by TNF much more strongly than the activation of the same kinases by other cytokines or growth factors (47, 48). Therefore, we compared the effects of NaSal on Ikappa Balpha degradation induced by TNF and by IL-1 (Fig. 2). Ikappa Balpha degradation induced by TNF was completely inhibited, whereas Ikappa Balpha degradation elicited by treatment with IL-1 was much less affected. The selectivity of NaSal's inhibitory action on TNF-induced Ikappa Balpha degradation is supported by the finding that prior treatment of cells with NaSal and TNF did not prevent the ability of IL-1 to induce Ikappa Balpha degradation, as shown in the last lane of Fig. 2. The latter finding shows that treatment with NaSal and TNF does not render Ikappa Balpha refractory to phosphorylation by the IL-1-triggered pathway.


View larger version (26K):
[in this window]
[in a new window]
  		FIG. 2.   Selective inhibition of TNF-induced Ikappa Balpha degradation by NaSal. COS-1 cells were preincubated for 1 h in the presence (+) or absence (-) of NaSal (20 mM). They were then left untreated (Ctrl) or treated with TNF (20 ng/ml) or IL-1 (4 ng/ml) for 15 min. In the last two lanes, an initial 15-min TNF treatment was immediately followed by a 15-min IL-1 treatment. Lysates were blotted with anti-Ikappa Balpha antibody.

The inhibitory action of NaSal on TNF-induced Ikappa Balpha phosphorylation and degradation is prevented by selective inhibition of p38 MAPK activity. We have recently demonstrated that NaSal treatment of normal human fibroblasts or COS-1 cells leads to an activation of the p38 MAPK and that NaSal-induced p38 MAPK activation is required for apoptosis induced by NaSal in human fibroblasts (47). In view of the demonstrated inverse relationship between apoptosis and NF-kappa B activity (5, 32, 52, 55), we considered the possibility that p38 promotes NaSal-induced apoptosis by inhibiting NF-kappa B function. To determine whether NaSal-induced inhibition of Ikappa Balpha phosphorylation and degradation was mediated by p38, we used a highly specific p38 kinase inhibitor, the pyridinyl imidazole compound SB203580 (14, 29, 58, 60). The ability of NaSal to inhibit TNF-induced Ikappa Balpha phosphorylation was largely prevented in both COS-1 and HT-29 cells that were treated with SB203580 before their exposure to TNF (Fig. 3A, upper panel). In both types of cells, a 5-min treatment with TNF induced the appearance of the phosphorylated form of Ikappa Balpha (lane 2), which was inhibited by the addition of NaSal (lane 4). Whereas treatment of cells with SB203580 in the absence of NaSal did not affect TNF-induced Ikappa Balpha phosphorylation (lane 6), the inhibitory activity of NaSal on Ikappa Balpha phosphorylation was largely prevented when cells were treated with SB203580 before their exposure to NaSal and TNF (lane 8). In a similar type of experiment, we also examined the effect of SB203580 on the ability of NaSal to inhibit TNF-induced Ikappa Balpha degradation (Fig. 3B). A 15-min treatment of either COS-1 or HT-29 cells with TNF led to the disappearance of the Ikappa Balpha band from the cell extracts, indicating that Ikappa Balpha had been intracellularly degraded (lane 2). This TNF-induced Ikappa Balpha degradation was inhibited by treatment with NaSal (lane 4). Whereas SB203580 did not affect TNF-induced Ikappa Balpha degradation in the absence of NaSal (lane 6), treatment with the p38 kinase inhibitor significantly prevented the ability of NaSal to suppress TNF-induced Ikappa Balpha degradation (lane 8). Similar results were obtained when we examined the effect of SB203580 on the ability of NaSal to inhibit Ikappa Bbeta degradation (50). Treatment with NaSal blocked TNF-induced degradation of Ikappa Bbeta in HT-29 cells, and this blockage was prevented upon treatment with SB203580 (data not shown).


View larger version (35K):
[in this window]
[in a new window]
  		FIG. 3.   Inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation by NaSal is prevented by SB203580. (A) COS-1 and HT-29 cells were preincubated for 1.5 h in the presence (+) or absence (-) of SB203580 (10 µM). The cells were then incubated for 1 h in the presence or absence of NaSal (20 mM) and subsequently incubated for 5 min in the presence or absence of TNF (20 ng/ml). Lysates were blotted with antibodies against phosphorylated Ikappa Balpha (pIkappa B-alpha ; top panel) and with antibodies to Ikappa Balpha (bottom panel). (B) COS-1 and HT-29 cells were treated as described above except that the duration of TNF treatment was 15 min instead of 5 min. Lysates were blotted with anti-Ikappa Balpha antibody.

Induction of p38 MAPK by NaSal correlates with the inhibitory action on TNF-induced Ikappa Balpha phosphorylation and degradation. The finding that inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation by NaSal was prevented in the presence of SB203580 strongly suggested that the earlier demonstrated induction of p38 MAPK activation by NaSal (47) plays a role in this process. To further analyze the role of p38, we compared the kinetics of the inhibition of TNF-induced Ikappa Balpha phosphorylation with the kinetics of p38 activation by NaSal. COS-1 cells were treated with NaSal for periods ranging from 30 s to 1 h before their exposure to TNF, and the extent of Ikappa Balpha degradation was determined at 15 min after TNF addition (Fig. 4A). Treatment with NaSal for 30 s was sufficient to produce a detectable inhibition of Ikappa Balpha degradation, although the degree of inhibition increased with longer periods of NaSal pretreatment. An analysis of the kinetics of p38 activation (determined by the appearance of a band specifically recognized by antibody to phosphorylated p38) revealed that phospho-p38 was detectable within 30 s and reached a plateau at 5 min after NaSal addition (Fig. 4B). We (reference 47 and data not shown) and others (43) have shown that p38 phosphorylation correlates with kinase activity. Thus, p38 activation by NaSal is extremely rapid, as is the establishment of the inhibitory action of NaSal on Ikappa Balpha degradation.


View larger version (43K):
[in this window]
[in a new window]
  		FIG. 4.   Kinetics of inhibition of Ikappa Balpha degradation and of p38 MAPK activation by NaSal. (A) COS-1 cells were either left untreated (-) or treated for the indicated times with NaSal (20 mM) and then stimulated for 15 min with TNF (20 ng/ml). Lysates were blotted with anti-Ikappa Balpha antibody. (B) COS-1 cells were treated for the indicated times with NaSal (20 mM) alone, lysed, and blotted with anti-phospho-p38 MAPK antibody (pp38; top panel) and with anti-p38 MAPK antibody (p38; bottom panel).

To further analyze the correlation between p38 MAPK activation and the inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation by NaSal, we examined the abilities of different doses of NaSal to inhibit TNF-induced Ikappa Balpha degradation and to activate p38 MAPK. A very strong inhibition of TNF-induced Ikappa Balpha degradation was seen in COS-1 cells with 20 and 10 mM NaSal, while 5 mM produced a strong, and 2 mM NaSal produced a slight, inhibition (Fig. 5A). Similarly, although 20 mM NaSal was required for an optimal activation of p38 (as measured by the appearance of phospho-p38), 2 mM was sufficient to produce a detectable activation. Thus, the dose responses of p38 activation and inhibition of Ikappa Balpha phosphorylation and degradation by NaSal are very similar. Taken together, these findings support the conclusion that p38 activation by NaSal, either alone or in conjunction with some other action, is responsible for the inhibition of TNF-induced Ikappa Balpha phosphorylation and subsequent degradation.


View larger version (45K):
[in this window]
[in a new window]
  		FIG. 5.   Inhibition of Ikappa Balpha degradation and induction of p38 MAPK activation by different doses of NaSal. (A) COS-1 cells were treated for 15 min with the indicated doses of NaSal and then left unstimulated (-) or stimulated (+) for 15 min with TNF (20 ng/ml). Lysates were blotted with anti-Ikappa Balpha antibody. (B) COS-1 cells were treated for 15 min with the indicated doses of NaSal alone, lysed, and blotted with anti-phospho-p38 MAPK antibody (pp38; top panel) and with anti-p38 MAPK antibody (p38; bottom panel).

NaSal activates p38 MAPK more rapidly than TNF. TNF itself is known to be a potent activator of p38 MAPK (31, 43), raising the question of what the role of TNF-induced p38 activation is in the process of Ikappa Balpha phosphorylation and degradation. If p38 activation leads to an inhibition of Ikappa Balpha phosphorylation, how is TNF able to induce both Ikappa Balpha phosphorylation and p38 activation? To resolve this paradox, we compared the kinetics of p38 activation in COS-1 cells treated with either TNF or NaSal (Fig. 6). An increase in p38 phosphorylation was detected 5 min after TNF addition, whereas incubation of cells in the presence of TNF for 1 or 2 min did not result in a demonstrable p38 activation. In contrast, a marked activation of p38 was demonstrable within 1 min of NaSal addition. The same results were obtained when the kinetics of TNF- and NaSal-induced p38 activation were compared in HT-29 cells (data not shown). Other experiments showed that p38 activation in NaSal-treated cells remained strong for at least 8 h (data not shown). The fact that it takes about 5 min for TNF to produce p38 MAPK activation may explain why p38 activation by TNF fails to prevent TNF-induced Ikappa Balpha phosphorylation and degradation. Since Ikappa B-alpha phosphorylation also peaks at about 5 min after TNF addition (Fig. 1), TNF-induced p38 activation probably does not occur early enough to prevent Ikappa Balpha phosphorylation and its subsequent degradation leading to NF-kappa B activation.


View larger version (35K):
[in this window]
[in a new window]
  		FIG. 6.   Kinetics of p38 MAPK activation by NaSal and TNF. COS-1 cells were either left untreated (Ctrl) or treated for the indicated times with TNF (20 ng/ml) or NaSal (20 mM). Lysates were blotted with anti-phospho-p38 MAPK antibody (pp38; top panel) and with anti-p38 MAPK antibody (p38; bottom panel).

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The inhibition of NF-kappa B activation by NaSal and aspirin has been widely documented in a variety of cell systems (16, 18, 25, 42). NaSal was shown to inhibit the phosphorylation of Ikappa Balpha that precedes Ikappa Balpha degradation by the ubiquitin-proteasome pathway and leads to the release of activated NF-kappa B (25, 42). However, the pathway responsible for the inhibition of Ikappa Balpha phosphorylation by NaSal has not been elucidated. A recent study from our laboratory showed that treatment of cells with NaSal results in p38 MAPK activation, as demonstrated in a direct kinase assay with glutathione S-transferase-ATF2 as the substrate and by a demonstration of increased p38 phosphorylation (47). The latter demonstration raised the possibility that p38 MAPK activation by NaSal may play a role in some of the anti-inflammatory actions of NaSal, including its inhibition of TNF-induced Ikappa Balpha phosphorylation and subsequent degradation. The present study provides evidence that p38 MAPK activity is required for the inhibitory action of NaSal on TNF-induced Ikappa Balpha phosphorylation and degradation, based on the demonstration that treatment of cells with a highly selective p38 kinase inhibitor, the pyridinyl imidazole compound SB203580, prevented the ability of NaSal to suppress both the phosphorylation and degradation of Ikappa Balpha induced by TNF (Fig. 3). SB203580 binds with a high affinity to p38 near the ATP binding site, thus rendering p38 inactive (60). At the concentration of 10 µM used in our experiments, SB203580 fails to affect other kinases, including other MAPKs in intact cells (14, 58). To further substantiate the conclusion that p38 activation by NaSal is required for the inhibitory action of NaSal on TNF-induced Ikappa Balpha phosphorylation, we also compared the kinetics (Fig. 4) and the dose response (Fig. 5) of p38 activation and of the inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation by NaSal. The results of the latter experiments show that p38 activation by NaSal correlates with its inhibitory activity on TNF-induced Ikappa Balpha phosphorylation and subsequent degradation.

NaSal was much less effective in inhibiting IL-1-induced Ikappa Balpha degradation than Ikappa Balpha degradation induced by TNF (Fig. 2). Earlier, we showed that in normal human fibroblasts, NaSal strongly inhibited ERK and JNK/SAPK activation by TNF but was much less effective in inhibiting activation of these MAPKs by other agents, e.g., epidermal growth factor or IL-1 (47, 48). Thus, our earlier and present findings support the notion that a principal target of NaSal action is an early event in TNF-triggered signaling that leads to Ikappa Balpha phosphorylation as well as to ERK and JNK/SAPK activation. Among the possible targets are TRAF2, a signaling protein implicated in both NF-kappa B and JNK/SAPK activation by TNF (20, 32, 44), and RIP, found to be essential for TNF-induced NF-kappa B activation (51). Others, however, have reported that NaSal efficiently inhibited NF-kappa B activation induced by bacterial lipopolysaccharide (40), insulin (7), human immunodeficiency virus Tat protein (15), or respiratory syncytial virus infection (9), suggesting that at least under some circumstances, the inhibitory effect of NaSal is not specific for TNF-induced NF-kappa B activation.

Although our experiments demonstrate that p38 MAPK is required for the inhibitory effect on TNF-induced Ikappa Balpha phosphorylation, it is not known whether p38 activation is sufficient for the establishment of the inhibition or whether some other NaSal-induced action is also necessary. Many stimuli that lead to p38 kinase activation also result in the activation of the JNK/SAPK subfamily of MAPKs (43). In fact, we have seen that treatment with NaSal leads to an activation of JNK/SAPK in both COS-1 and HT-29 cells (data not shown). Thus, we cannot rule out the possibility that activation of both p38 and JNK/SAPK is required for NaSal-induced inhibition of TNF-induced Ikappa Balpha phosphorylation and degradation. Alternatively, it might be possible that some other unknown function activated by NaSal, together with p38 activation, is required for the inhibitory action.

Actions of NSAIDs may be divided into two categories: those that are mediated by inhibition of prostaglandin biosynthesis and those that are independent of effects on prostaglandin synthesis (57). For a number of reasons, the activation of p38 by NaSal very likely falls within the latter category. First, unlike other NSAIDs, NaSal is known to be a weak inhibitor of both cyclooxygenase isoforms (COX1 and COX2) and, hence, of prostaglandin synthesis (37). Even more importantly, our demonstration that p38 kinase activation was evident within 30 s to 1 min of NaSal addition (Fig. 4 and 6) makes it very unlikely that this action was secondary to an inhibition of prostaglandin synthesis.

Recent evidence indicates the existence of four distinct isoforms of p38 MAPK, termed p38alpha , p38beta , p38gamma /SAPK3, and p38delta /SAPK4 (13, 21, 26, 28, 30). The four isoforms are similar in size (360 to 372 amino acids in length), show about 60 to 75% sequence homology, and are all activated by TNF, IL-1, UV radiation, and hyperosmolar medium, but they differ in substrate specificity and in susceptibility to inhibition by SB203580. Since one study found that p38alpha and p38beta , but not p38gamma and p38delta , were inhibited by SB203580 (26), it seems less likely that either the gamma  or the delta  isoform is responsible for the inhibition of Ikappa Balpha phosphorylation by NaSal. Availability of expression vectors encoding the individual tagged p38 isoforms should make it possible to test directly which of the four isoforms can be activated by NaSal and which is able to inhibit Ikappa Balpha phosphorylation.

Since TNF itself potently activates p38 MAPK (31, 43) as well as inducing Ikappa Balpha phosphorylation, our finding that p38 mediates the inhibition of the latter process at first seemed difficult to reconcile. However, a careful comparison of the kinetics of p38 activation and Ikappa Balpha phosphorylation in TNF-treated cells may help to explain these seemingly paradoxical observations. Both Ikappa Balpha phosphorylation (Fig. 1) and p38 activation (Fig. 6) are first demonstrable at about 5 min after the exposure of cells to TNF. Thus, p38 activation by TNF probably occurs too late to prevent Ikappa Balpha phosphorylation. On the other hand, our findings raise the distinct possibility that TNF-induced p38 activation plays a negative autoregulatory role in the process of Ikappa Balpha phosphorylation and degradation. It is known that TNF-induced Ikappa Balpha degradation is quite transient and that the Ikappa Balpha protein rapidly reappears even when cells are kept in the continuous presence of TNF (6, 49). In both TNF-treated COS-1 cells (Fig. 1B) and HT-29 cells (data not shown), reappearance of Ikappa Balpha was apparent as soon as 30 min after TNF addition. Ikappa Balpha reappearance is the result of rapid Ikappa Balpha resynthesis, a process that is promoted by the NF-kappa B transcription factor (39). In view of our findings, it is plausible that another factor aiding in the rapid reappearance of Ikappa Balpha is p38 activation by TNF, which may serve to prevent Ikappa Balpha phosphorylation and resulting degradation of the newly synthesized Ikappa Balpha protein.

There is evidence that under some circumstances, p38 MAPK activation promotes apoptosis (22, 24, 47, 59). There is also extensive evidence showing that NF-kappa B activation suppresses apoptosis, most likely because NF-kappa B promotes the synthesis of proteins that can protect cells from apoptosis (5, 32, 52, 55). Our findings suggest that the propensity of p38 MAPK to promote apoptosis could be at least partly due to the inhibition of NF-kappa B activation by p38. However, other factors are likely to be involved in these processes because, in two different cell systems, we and others were unable to demonstrate a significant protection from TNF-induced apoptosis by incubating cells in the presence of the p38 kinase inhibitor SB203580 (8, 47).

Earlier we demonstrated that SB203580 inhibits apoptosis induced by NaSal in cultured diploid human fibroblasts, indicating that p38 activation by NaSal was essential for this process (47). Based on this earlier work, we concluded that the activation of p38 MAPK and the resulting induction of apoptosis may be important in the widely demonstrated antineoplastic actions of aspirin and other NSAIDs. Our present findings suggest that p38 activation and the resulting inhibition of TNF-induced NF-kappa B activation are of some significance in the anti-inflammatory actions of NSAIDs. To inhibit NF-kappa B activation and NF-kappa B-mediated actions in cultured cells, many investigators relied on high doses of NaSal (usually 20 mM) that are unlikely to be achievable systemically in the intact organism without producing severe toxic side effects (11). However, concentrations of salicylates that are locally available may be increased in the mildly acidic environments that prevail at inflammatory sites (1, 57). Moreover, our present study shows that a significant activation of p38 kinase and inhibition of Ikappa Balpha phosphorylation and degradation can be achieved with 2 to 5 mM NaSal (Fig. 5), which is a dose range achievable upon systemic administration of salicylates during anti-inflammatory therapy (1). These findings support the notion that the observations reported in the present study are relevant to some of the anti-inflammatory actions of NSAIDs in the intact organism.

    ACKNOWLEDGMENTS

We thank John C. Lee, Peter Young, Jiahuai Han, Gerald Weissmann, and Bruce Cronstein for reagents and helpful discussions and Ilene Totillo for preparing the manuscript.

This work was supported by NIH grant R35CA42568. P.S. was supported by a predoctoral fellowship from NIH training grant 5T32-CA09161. D.A. was supported by an MSTP fellowship from NIH training grant 5T32-GM07308.

    FOOTNOTES

* Corresponding author. Mailing address: Department of Microbiology, New York University Medical Center, 550 First Ave., New York, NY 10016. Phone: (212) 263-6756. Fax: (212) 263-7933. E-mail: vilcej01{at}mcrcr.med.nyu.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Abramson, S. B., and G. Weissmann. 1989. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 32:1-9[Medline].
2. Baeuerle, P. A., and D. Baltimore. 1996. NF-kappa B: ten years after. Cell 87:13-20[Medline].
3. Baldwin, A. S., Jr. 1996. The NF-kappa B and Ikappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649-683[Medline].
4. Beauparlant, P., and J. Hiscott. 1996. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7:175-190. [Medline]
5. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-kappa B in preventing TNF-alpha -induced cell death. Science 274:782-784[Abstract/Free Full Text].
6. Beg, A. A., T. S. Finco, P. V. Nantermet, and A. S. Baldwin, Jr. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of Ikappa Balpha : a mechanism for NF-kappa B activation. Mol. Cell. Biol. 13:3301-3310[Abstract/Free Full Text].
7. Bertrand, F., C. Philippe, P. J. Antoine, L. Baud, A. Groyer, J. Capeau, and G. Cherqui. 1995. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J. Biol. Chem. 270:24435-24441[Abstract/Free Full Text].
8. Beyaert, R., A. Cuenda, W. Vanden Berghe, S. Plaisance, J. C. Lee, G. Haegeman, P. Cohen, and W. Fiers. 1996. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor. EMBO J. 15:1914-1923[Medline].
9. Bitko, V., A. Velazquez, L. Yang, Y. C. Yang, and S. Barik. 1997. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology 232:369-378[Medline].
10. Cano, E., and L. C. Mahadevan. 1995. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20:117-122[Medline].
11. Chalasani, N., J. Roman, and R. L. Jurado. 1996. Systemic inflammatory response syndrome caused by chronic salicylate intoxication. South. Med. J. 89:479-482[Medline].
12. Connelly, M. A., and K. B. Marcu. 1995. CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain. Cell. Mol. Biol. Res. 41:537-549[Medline].
13. Cuenda, A., P. Cohen, V. Buee-Scherrer, and M. Goedert. 1997. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 16:295-305[Medline].
14. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, and J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229-233[Medline].
15. Demarchi, F., F. d'Adda di Fagagna, A. Falaschi, and M. Giacca. 1996. Activation of transcription factor NF-kappa B by the Tat protein of human immunodeficiency virus type 1. J. Virol. 70:4427-4437[Abstract].
16. Gautam, S. C., K. R. Pindolia, C. J. Noth, N. Janakiraman, Y. X. Xu, and R. A. Chapman. 1995. Chemokine gene expression in bone marrow stromal cells: downregulation with sodium salicylate. Blood 86:2541-2550[Abstract/Free Full Text].
17. Graves, J. D., K. E. Draves, A. Craxton, J. Saklatvala, E. G. Krebs, and E. A. Clark. 1996. Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mlgM-induced apoptosis of human B lymphocytes. Proc. Natl. Acad. Sci. USA 93:13814-13818[Abstract/Free Full Text].
18. Grilli, M., M. Pizzi, M. Memo, and P. Spano. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappa B activation. Science 274:1383-1385[Abstract/Free Full Text].
19. Gupta, S., T. Barrett, A. J. Whitmarsh, J. Cavanagh, H. K. Sluss, B. Dérijard, and R. J. Davis. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770[Medline].
20. Hsu, H., H.-B. Shu, M.-G. Pan, and D. V. Goeddel. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308[Medline].
21. Jiang, Y., C. Chen, Z. Li, W. Guo, J. A. Gegner, S. Lin, and J. Han. 1996. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta ). J. Biol. Chem. 271:17920-17926[Abstract/Free Full Text].
22. Juo, P., C. J. Kuo, S. E. Reynolds, R. F. Konz, J. Raingeaud, R. J. Davis, H. P. Biemann, and J. Blenis. 1997. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 17:24-35[Abstract].
23. Kawasaki, H., T. Morooka, S. Shimohama, J. Kimura, T. Hirano, Y. Gotoh, and E. Nishida. 1997. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 272:18518-18521[Abstract/Free Full Text].
24. Kinoshita, T., T. Yokota, K. Arai, and A. Miyajima. 1995. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J. 14:266-275[Medline].
25. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959[Abstract/Free Full Text].
26. Kumar, S., P. C. McDonnell, R. J. Gum, A. T. Hand, J. C. Lee, and P. R. Young. 1997. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235:533-538[Medline].
27. Kyriakis, J. M., P. Banerjee, E. Nikolakaki, T. Dai, E. A. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgett. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160[Medline].
28. Lechner, C., M. A. Zahalka, J. F. Giot, N. P. Moller, and A. Ullrich. 1996. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc. Natl. Acad. Sci. USA 93:4355-4359[Abstract/Free Full Text].
29. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, J. E. Strickler, M. M. McLaughlin, I. R. Siemens, S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, and P. R. Young. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746[Medline].
30. Li, Z., Y. Jiang, R. J. Ulevitch, and J. Han. 1996. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228:334-340[Medline].
31. Lin, A., A. Minden, H. Martinetto, F. X. Claret, C. Lange-Carter, F. Mercurio, G. L. Johnson, and M. Karin. 1995. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268:286-290[Abstract/Free Full Text].
32. Liu, Z.-G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death. Cell 87:565-576[Medline].
33. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NF-kappa B induction by TNF, CD95 and IL-1. Nature 385:540-544[Medline].
34. Marshall, C. J. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185[Medline].
35. Minden, A., A. Lin, M. McMahon, C. Lange-Carter, B. Dérijard, R. J. Davis, G. L. Johnson, and M. Karin. 1994. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723[Abstract/Free Full Text].
36. Minden, A., A. Lin, T. Smeal, B. Dérijard, M. Cobb, R. Davis, and M. Karin. 1994. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol. Cell. Biol. 14:6683-6688[Abstract/Free Full Text].
37. Mitchell, J. A., P. Akarasereenont, C. Thiemermann, R. J. Flower, and J. R. Vane. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90:11693-11697[Abstract/Free Full Text].
38. Miyamoto, S., M. Maki, M. J. Schmitt, M. Hatanaka, and I. M. Verma. 1994. Tumor necrosis factor alpha -induced phosphorylation of Ikappa Balpha is a signal for its degradation but not dissociation from NF-kappa B. Proc. Natl. Acad. Sci. USA 91:12740-12744[Abstract/Free Full Text].
39. Miyamoto, S., and I. M. Verma. 1995. Rel/NF-kappa B/Ikappa B story. Adv. Cancer Res. 66:255-292[Medline].
40. Oeth, P., and N. Mackman. 1995. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood 86:4144-4152[Abstract/Free Full Text].
41. Palombella, V. J., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785[Medline].
42. Pierce, J. W., M. A. Read, H. Ding, F. W. Luscinskas, and T. Collins. 1996. Salicylates inhibit Ikappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 156:3961-3969[Abstract].
43. Raingeaud, J., S. Gupta, J. S. Rogers, M. Dickens, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:7420-7426[Abstract/Free Full Text].
44. Regnier, C. H., H. Y. Song, X. Gao, D. V. Goeddel, Z. Cao, and M. Rothe. 1997. Identification and characterization of an Ikappa B kinase. Cell 90:373-383[Medline].
45. Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:180-186[Medline].
46. Sanchez, I., R. T. Hughes, B. J. Mayer, K. Yee, J. R. Woodgett, J. Avruch, J. M. Kyriakis, and L. I. Zon. 1994. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-798[Medline].
47. Schwenger, P., P. Bellosta, I. Vietor, C. Basilico, E. Y. Skolnik, and J. Vilcek. 1997. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 94:2869-2873[Abstract/Free Full Text].
48. Schwenger, P., E. Y. Skolnik, and J. Vilcek. 1996. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase by sodium salicylate. J. Biol. Chem. 271:8089-8094[Abstract/Free Full Text].
49. Sun, S. C., P. A. Ganchi, C. Beraud, D. W. Ballard, and W. C. Greene. 1994. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. USA 91:1346-1350[Abstract/Free Full Text].
50. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh. 1995. Ikappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 80:573-582[Medline].
51. Ting, A. T., F. X. Pimentel-Muinos, and B. Seed. 1996. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappa B but not Fas/APO-1-initiated apoptosis. EMBO J. 15:6189-6196[Medline].
52. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNF-alpha -induced apoptosis by NF-kappa B. Science 274:787-789[Abstract/Free Full Text].
53. Van Lint, J., P. Agostinis, V. Vandevoorde, G. Haegeman, W. Fiers, W. Merlevede, and J. R. Vandenheede. 1992. Tumor necrosis factor stimulates multiple serine/threonine protein kinases in Swiss 3T3 and L929 cells. Implication of casein kinase-2 and extracellular signal-regulated kinases in the tumor necrosis factor signal transduction pathway. J. Biol. Chem. 267:25916-25921[Abstract/Free Full Text].
54. Vietor, I., P. Schwenger, W. Li, J. Schlessinger, and J. Vilcek. 1993. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J. Biol. Chem. 268:18994-18999[Abstract/Free Full Text].
55. Wang, C.-Y., M. W. Mayo, and A. S. Baldwin, Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science 274:784-787[Abstract/Free Full Text].
56. Wang, X. Z., and D. Ron. 1996. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 272:1347-1349[Abstract].
57. Weissmann, G. 1991. Aspirin. Sci. Am. 264:84-90[Medline].
58. Whitmarsh, A. J., S.-H. Yang, M. S.-S. Su, A. D. Sharrocks, and R. J. Davis. 1997. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol. Cell. Biol. 17:2360-2371[Abstract].
59. Xia, Z., M. Dickens, J. Raingeaud, R. J. Davis, and M. E. Greenberg. 1995. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331[Abstract/Free Full Text].
60. Young, P. R., M. M. McLaughlin, S. Kumar, S. Kassis, M. L. Doyle, D. McNulty, T. F. Gallagher, S. Fisher, P. C. McDonnell, S. A. Carr, M. J. Huddleston, G. Seibel, T. G. Porter, G. P. Livi, J. L. Adams, and J. C. Lee. 1997. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272:12116-12121[Abstract/Free Full Text].

Mol Cell Biol, January 1998, p. 78-84, Vol. 18, No. 1
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fang, X., Feng, Y., Shi, Z., Dai, J. (2009). Alterations of Cytokines and MAPK Signaling Pathways are Related to the Immunotoxic Effect of Perfluorononanoic Acid. Toxicol Sci 108: 367-376 [Abstract] [Full Text]  
  • Sapienza, K., Bannister, W., Balzan, R. (2008). Mitochondrial involvement in aspirin-induced apoptosis in yeast. Microbiology 154: 2740-2747 [Abstract] [Full Text]  
  • D'Alimonte, I., Flati, V., D'Auro, M., Toniato, E., Martinotti, S., Rathbone, M. P., Jiang, S., Ballerini, P., Di Iorio, P., Caciagli, F., Ciccarelli, R. (2007). Guanosine Inhibits CD40 Receptor Expression and Function Induced by Cytokines and beta Amyloid in Mouse Microglia Cells. J. Immunol. 178: 720-731 [Abstract] [Full Text]  
  • Derouet, M., Thomas, L., Moulding, D. A., Akgul, C., Cross, A., Moots, R. J., Edwards, S. W. (2006). Sodium Salicylate Promotes Neutrophil Apoptosis by Stimulating Caspase-Dependent Turnover of Mcl-1. J. Immunol. 176: 957-965 [Abstract] [Full Text]  
  • Mishra, S., Mishra, J. P., Gee, K., McManus, D. C., LaCasse, E. C., Kumar, A. (2005). Distinct Role of Calmodulin and Calmodulin-dependent Protein Kinase-II in Lipopolysaccharide and Tumor Necrosis Factor-{alpha}-mediated Suppression of Apoptosis and Antiapoptotic c-IAP2 Gene Expression in Human Monocytic Cells. J. Biol. Chem. 280: 37536-37546 [Abstract] [Full Text]  
  • Ariyoshi, W., Takahashi, T., Kanno, T., Ichimiya, H., Takano, H., Koseki, T., Nishihara, T. (2005). Mechanisms Involved in Enhancement of Osteoclast Formation and Function by Low Molecular Weight Hyaluronic Acid. J. Biol. Chem. 280: 18967-18972 [Abstract] [Full Text]  
  • Orr, A. W., Sanders, J. M., Bevard, M., Coleman, E., Sarembock, I. J., Schwartz, M. A. (2005). The subendothelial extracellular matrix modulates NF-{kappa}B activation by flow: a potential role in atherosclerosis. JCB 169: 191-202 [Abstract] [Full Text]  
  • Wu, D., Cederbaum, A. (2004). Glutathione Depletion in CYP2E1-Expressing Liver Cells Induces Toxicity Due to the Activation of p38 Mitogen-Activated Protein Kinase and Reduction of Nuclear Factor-{kappa}B DNA Binding Activity. Mol. Pharmacol. 66: 749-760 [Abstract] [Full Text]  
  • Mifflin, R. C., Saada, J. I., Di Mari, J. F., Valentich, J. D., Adegboyega, P. A., Powell, D. W. (2004). Aspirin-Mediated COX-2 Transcript Stabilization via Sustained p38 Activation in Human Intestinal Myofibroblasts. Mol. Pharmacol. 65: 470-478 [Abstract] [Full Text]  
  • Pillinger, M. H., Rosenthal, P. B., Tolani, S. N., Apsel, B., Dinsell, V., Greenberg, J., Chan, E. S. L., Gomez, P. F., Abramson, S. B. (2003). Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation. J. Immunol. 171: 6080-6089 [Abstract] [Full Text]  
  • Weber, N. C., Blumenthal, S. B., Hartung, T., Vollmar, A. M., Kiemer, A. K. (2003). ANP inhibits TNF-{alpha}-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1. J. Leukoc. Biol. 74: 932-941 [Abstract] [Full Text]  
  • Yoon, J.-B., Kim, S.-J., Hwang, S.-G., Chang, S., Kang, S.-S., Chun, J.-S. (2003). Non-steroidal Anti-inflammatory Drugs Inhibit Nitric Oxide-induced Apoptosis and Dedifferentiation of Articular Chondrocytes Independent of Cyclooxygenase Activity. J. Biol. Chem. 278: 15319-15325 [Abstract] [Full Text]  
  • Callejas, N. A., Fernandez-Martinez, A., Castrillo, A., Bosca, L., Martin-Sanz, P. (2003). Selective Inhibitors of Cyclooxygenase-2 Delay the Activation of Nuclear Factor kappa B and Attenuate the Expression of Inflammatory Genes in Murine Macrophages Treated with Lipopolysaccharide. Mol. Pharmacol. 63: 671-677 [Abstract] [Full Text]  
  • Von der Thusen, J. H., Kuiper, J., Van Berkel, T. J. C., Biessen, E. A. L. (2003). Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential. Pharmacol. Rev. 55: 133-166 [Abstract] [Full Text]  
  • Zhou, H.-R., Islam, Z., Pestka, J. J. (2003). Rapid, Sequential Activation of Mitogen-Activated Protein Kinases and Transcription Factors Precedes Proinflammatory Cytokine mRNA Expression in Spleens of Mice Exposed to the Trichothecene Vomitoxin. Toxicol Sci 72: 130-142 [Abstract] [Full Text]  
  • Wu, D., Cederbaum, A. I. (2003). Role of p38 MAPK in CYP2E1-dependent Arachidonic Acid Toxicity. J. Biol. Chem. 278: 1115-1124 [Abstract] [Full Text]  
  • Kontoyiannis, D., Boulougouris, G., Manoloukos, M., Armaka, M., Apostolaki, M., Pizarro, T., Kotlyarov, A., Forster, I., Flavell, R., Gaestel, M., Tsichlis, P., Cominelli, F., Kollias, G. (2002). Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor-induced Crohn's-like Inflammatory Bowel Disease. JEM 196: 1563-1574 [Abstract] [Full Text]  
  • Chen, C.-J., Raung, S.-L., Kuo, M.-D., Wang, Y.-M. (2002). Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J. Gen. Virol. 83: 1897-1905 [Abstract] [Full Text]  
  • Thun, M. J., Henley, S. J., Patrono, C. (2002). Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. JNCI J Natl Cancer Inst 94: 252-266 [Abstract] [Full Text]  
  • Perez-G., M., Melo, M., Keegan, A. D., Zamorano, J. (2002). Aspirin and Salicylates Inhibit the IL-4- and IL-13-Induced Activation of STAT6. J. Immunol. 168: 1428-1434 [Abstract] [Full Text]  
  • Zugasti, O., Rul, W., Roux, P., Peyssonnaux, C., Eychene, A., Franke, T. F., Fort, P., Hibner, U. (2001). Raf-MEK-Erk Cascade in Anoikis Is Controlled by Rac1 and Cdc42 via Akt. Mol. Cell. Biol. 21: 6706-6717 [Abstract] [Full Text]  
  • TEGEDER, I., PFEILSCHIFTER, J., GEISSLINGER, G. (2001). Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15: 2057-2072 [Abstract] [Full Text]  
  • Liao, C.-L., Lin, Y.-L., Wu, B.-C., Tsao, C.-H., Wang, M.-C., Liu, C.-I, Huang, Y.-L., Chen, J.-H., Wang, J.-P., Chen, L.-K. (2001). Salicylates Inhibit Flavivirus Replication Independently of Blocking Nuclear Factor Kappa B Activation. J. Virol. 75: 7828-7839 [Abstract] [Full Text]  
  • Detmer, K., Wang, Z., Warejcka, D., Leeper-Woodford, S. K., Newman, W. H. (2001). Endotoxin stimulated cytokine production in rat vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 281: H661-H668 [Abstract] [Full Text]  
  • Blandin, V., Vigne, P., Breittmayer, J. P., Frelin, C. (2001). Allosteric Inhibition of Endothelin ETA Receptors by 3,5-Dibromosalicylic Acid. Mol. Pharmacol. 58: 1461-1469 [Abstract] [Full Text]  
  • Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M., Englaro, W., Schoonjans, K., Derijard, B., Desvergne, B., Wahli, W., Chambon, P., Leibowitz, M. D., Colombel, J.-F., Auwerx, J. (2001). Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator-Activated Receptor {gamma} (Ppar{gamma}) Heterodimer: A Basis for New Therapeutic Strategies. JEM 193: 827-838 [Abstract] [Full Text]  
  • Murphy, G. A., Jillian, S. A., Michaelson, D., Philips, M. R., D’Eustachio, P., Rush, M. G. (2001). Signaling Mediated by the Closely Related Mammalian Rho Family GTPases TC10 and Cdc42 Suggests Distinct Functional Pathways. Cell Growth Differ. 12: 157-167 [Abstract] [Full Text]  
  • van den Blink, B., Juffermans, N. P., ten Hove, T., Schultz, M. J., van Deventer, S. J. H., van der Poll, T., Peppelenbosch, M. P. (2001). p38 Mitogen-Activated Protein Kinase Inhibition Increases Cytokine Release by Macrophages In Vitro and During Infection In Vivo. J. Immunol. 166: 582-587 [Abstract] [Full Text]  
  • Bowie, A. G., O'Neill, L. A. J. (2000). Vitamin C Inhibits NF-{kappa}B Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase. J. Immunol. 165: 7180-7188 [Abstract] [Full Text]  
  • Alpert, D., Vilcek, J. (2000). Inhibition of Ikappa B Kinase Activity by Sodium Salicylate in Vitro Does Not Reflect Its Inhibitory Mechanism in Intact Cells. J. Biol. Chem. 275: 10925-10929 [Abstract] [Full Text]  
  • Talbodec, A., Berkane, N., Blandin, V., Breittmayer, J. P., Ferrari, E., Frelin, C., Vigne, P. (2000). Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism. Mol. Pharmacol. 57: 797-804 [Abstract] [Full Text]  
  • Engelman, J. A., Berg, A. H., Lewis, R. Y., Lin, A., Lisanti, M. P., Scherer, P. E. (1999). Constitutively Active Mitogen-activated Protein Kinase Kinase 6 (MKK6) or Salicylate Induces Spontaneous 3T3-L1 Adipogenesis. J. Biol. Chem. 274: 35630-35638 [Abstract] [Full Text]  
  • Wang, Z., Brecher, P. (1999). Salicylate Inhibition of Extracellular Signal-Regulated Kinases and Inducible Nitric Oxide Synthase. Hypertension 34: 1259-1264 [Abstract] [Full Text]  
  • Gupta, A., Rosenberger, S. F., Bowden, G. T. (1999). Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 20: 2063-2073 [Abstract] [Full Text]  
  • Shiff, S. J., Rigas, B. (1999). The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids). JEM 190: 445-450 [Full Text]  
  • Alpert, D., Schwenger, P., Han, J. (1999). Cell Stress and MKK6b-mediated p38 MAP Kinase Activation Inhibit Tumor Necrosis Factor-induced Ikappa B Phosphorylation and NF-kappa B Activation. J. Biol. Chem. 274: 22176-22183 [Abstract] [Full Text]  
  • Lemay, S., Lebedeva, T. V., Singh, A. K. (1999). Inhibition of Cytokine Gene Expression by Sodium Salicylate in a Macrophage Cell Line through an NF-kappa B-Independent Mechanism. CVI 6: 567-572 [Abstract] [Full Text]  
  • Eliopoulos, A. G., Gallagher, N. J., Blake, S. M. S., Dawson, C. W., Young, L. S. (1999). Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production. J. Biol. Chem. 274: 16085-16096 [Abstract] [Full Text]  
  • Liu, R. Y., Fan, C., Olashaw, N. E., Wang, X., Zuckerman, K. S. (1999). Tumor Necrosis Factor-alpha -induced Proliferation of Human Mo7e Leukemic Cells Occurs via Activation of Nuclear Factor kappa B Transcription Factor. J. Biol. Chem. 274: 13877-13885 [Abstract] [Full Text]  
  • Madge, L. A., Sierra-Honigmann, M. R., Pober, J. S. (1999). Apoptosis-inducing Agents Cause Rapid Shedding of Tumor Necrosis Factor Receptor 1 (TNFR1). A NONPHARMACOLOGICAL EXPLANATION FOR INHIBITION OF TNF-MEDIATED ACTIVATION. J. Biol. Chem. 274: 13643-13649 [Abstract] [Full Text]  
  • SCHREIBER;, S (1999). Activation of nuclear factor kappa B as a target for anti- inflammatory therapy. Gut 44: 309-310 [Full Text]  
  • Manna, S. K., Aggarwal, B. B. (1999). Lipopolysaccharide Inhibits TNF-Induced Apoptosis: Role of Nuclear Factor-{kappa}B Activation and Reactive Oxygen Intermediates. J. Immunol. 162: 1510-1518 [Abstract] [Full Text]  
  • SCHMID, R M, ADLER, G, LIPTAY, S, SCHREIBER, S, NIKOLAUS, S, HAMPE, J (1998). Activation of NFkappa B in inflammatory bowel disease • Reply. Gut 43: 586c-586 [Full Text]  
  • Du, M., Sansores-Garcia, L., Zu, Z., Wu, K. K.-y. (1998). Cloning and Expression Analysis of a Novel Salicylate Suppressible Gene, Hs-CUL-3, a Member of Cullin/Cdc53 Family. J. Biol. Chem. 273: 24289-24292 [Abstract] [Full Text]  
  • Matsumoto, M., Sudo, T., Saito, T., Osada, H., Tsujimoto, M. (2000). Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-kappa B Ligand (RANKL). J. Biol. Chem. 275: 31155-31161 [Abstract] [Full Text]  
  • Paik, J. H., Ju, J. H., Lee, J. Y., Boudreau, M. D., Hwang, D. H. (2000). Two Opposing Effects of Non-steroidal Anti-inflammatory Drugs on the Expression of the Inducible Cyclooxygenase. MEDIATION THROUGH DIFFERENT SIGNALING PATHWAYS. J. Biol. Chem. 275: 28173-28179 [Abstract] [Full Text]  
  • Poppers, D. M., Schwenger, P., Vilcek, J. (2000). Persistent Tumor Necrosis Factor Signaling in Normal Human Fibroblasts Prevents the Complete Resynthesis of Ikappa B-alpha. J. Biol. Chem. 275: 29587-29593 [Abstract] [Full Text]  
  • Law, B. K., Waltner-Law, M. E., Entingh, A. J., Chytil, A., Aakre, M. E., Norgaard, P., Moses, H. L. (2000). Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen. J. Biol. Chem. 275: 38261-38267 [Abstract] [Full Text]  
  • Silva, A. M., Reis, L. F. L. (2000). Sodium Salicylate Induces the Expression of the Immunophilin FKBP51 and Biglycan Genes and Inhibits p34cdc2 mRNA Both in Vitro and in Vivo. J. Biol. Chem. 275: 36388-36393 [Abstract] [Full Text]  
  • Saunders, M. A., Sansores-Garcia, L., Gilroy, D. W., Wu, K. K. (2001). Selective Suppression of CCAAT/Enhancer-binding Protein beta Binding and Cyclooxygenase-2 Promoter Activity by Sodium Salicylate in Quiescent Human Fibroblasts. J. Biol. Chem. 276: 18897-18904 [Abstract] [Full Text]  
  • Lee, J. Y., Sohn, K. H., Rhee, S. H., Hwang, D. (2001). Saturated Fatty Acids, but Not Unsaturated Fatty Acids, Induce the Expression of Cyclooxygenase-2 Mediated through Toll-like Receptor 4. J. Biol. Chem. 276: 16683-16689 [Abstract] [Full Text]  
  • Spiegelman, V. S., Stavropoulos, P., Latres, E., Pagano, M., Ronai, Z.'e., Slaga, T. J., Fuchs, S. Y. (2001). Induction of beta -Transducin Repeat-containing Protein by JNK Signaling and Its Role in the Activation of NF-kappa B. J. Biol. Chem. 276: 27152-27158 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwenger, P.
Right arrow Articles by Vilcek, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwenger, P.
Right arrow Articles by Vilcek, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»